Key Inflammatory Biomarkers in Perinatal Asphyxia: A Comprehensive Review
Lynn Bitar1, Barbara S Stonestreet2, Lina F Chalak1
1Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
Clinics in Perinatology
|August 2, 2024
Summary
Inflammatory biomarkers show promise in predicting the severity and outcomes of hypoxic-ischemia encephalopathy (HIE). Further research is needed to optimize their use in clinical decision-making for newborns with HIE.
Area of Science:
- Neonatal Medicine
- Biomarker Research
- Neurodevelopmental Pediatrics
Background:
- Hypoxic-ischemia encephalopathy (HIE) is a serious condition in newborns resulting from oxygen deprivation.
- Early identification and management of HIE are crucial for improving neurodevelopmental outcomes.
- Inflammatory processes play a significant role in the pathophysiology and progression of HIE.
Purpose of the Study:
- To summarize current evidence on placental and postnatal inflammatory biomarkers in HIE.
- To evaluate the diagnostic accuracy of these biomarkers for predicting HIE severity.
- To assess their utility in monitoring treatment response and predicting neurodevelopmental outcomes.
Main Methods:
- Systematic review of existing literature on inflammatory biomarkers and HIE.
- Analysis of studies reporting on diagnostic accuracy, treatment response assessment, and outcome prediction.
- Synthesis of findings related to both short- and long-term neurodevelopmental trajectories.
Main Results:
- Inflammatory biomarkers demonstrate potential in predicting HIE severity.
- Evidence suggests their value in assessing response to therapeutic interventions.
- Biomarkers may offer predictive insights into short- and long-term neurodevelopmental outcomes.
Conclusions:
- Inflammatory biomarkers can guide clinical decisions during the critical early stages of perinatal asphyxia.
- Additional research is essential to fully understand and optimize the utility of biomarkers for HIE management.
- Further investigation is needed to refine predictive models for HIE severity, evolution, and developmental outcomes.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
69
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
69
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
128
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
128